Back to Agenda
SESSION 4: Sample Management
Session Chair(s)
Neveen Kamel
Regulatory Affairs Head North Africa, Egypt & French-speaking Africa
Merck Group, Egypt
Zainab Aziz, MSc, RPh
IFPMA ARN Co-Chair & Associate Director, Regulatory Policy Middle East & Africa
Novartis, South Africa
Overview: This session will explore challenges associated with sample provision for Post-Approval Changes and promote best practices in Sample Management, leveraging Reliance pathways. The session will also highlight the development of a unified laboratory framework for sample testing through the Network of African Reliance Laboratories (NARL), the growing importance of post-marketing surveillance, share effective risk management strategies for product release post-importation and emphasise capacity building for local laboratories to detect substandard and falsified medicines.
Speaker(s)
Streamlining Sample Management to Strengthen Health Outcomes in Africa
Zainab Aziz, MSc, RPh
Novartis, South Africa
IFPMA ARN Co-Chair & Associate Director, Regulatory Policy Middle East & Africa
Reliance Frees up Capacity for Efficient Post-Marketing Surveillance of Medicines
Joerg Garbe, PhD, MSc
F. Hoffmann-La Roche Ltd, Switzerland
IFPMA In-Country Testing Taskforce Lead; Global Quality Manager & Policy Lead
Sample Management in the Context of Reliance for NDA and PACs
Neven Ahmed
Egyptian Drug Authority (EDA), Egypt
Reliance team leader
Sample Management overview – Qatar Experience
Noha Mohamed Reda Arram
Ministry of Public Health (MOPH), Qatar, Qatar
Head of Drug Quality Control Laboratory - Pharmacy & Drug Control Department
Panel Discussion with Q&A (With the additional participation of):
Assane Coulibaly
Autorité Ivoirienne de Régulation Pharmaceutique (AIRP) / Ivorian Pharm RA, Côte d'Ivoire
CEO / Director General
Have an account?